With Lilly JAK Tie-up, Incyte Aims To Chase Pfizer In Rheumatoid Arthritis
This article was originally published in The Pink Sheet Daily
Executive Summary
No time to lose: A deal for an earlier-stage oral drug underscores Big Pharma's passion for new targets in inflammatory diseases.
You may also be interested in...
With Much Riding On Fostamatinib, Rigel Awaits The Phase III Results
Dependent on revenues from AstraZeneca-partnered fostamatinib to fund its growth, Rigel has built a diverse and innovative portfolio. But disappointing results from a Phase IIb dose-ranging trial of fostamatinib – three other pivotal trials will report out soon – could signal trouble for the biopharma. Rigel execs Jim Gower and Raul Rodriguez share perspectives on the AstraZeneca deal and fostamatinib’s prospects.
Incyte's Grip On Myelofibrosis Tightens With Release Of Positive JAK Data, FDA Filing
Anemia rises but falls by end of treatment period in pivotal COMFORT-1 trial.
Incyte's Grip On Myelofibrosis Tightens With Release Of Positive JAK Data, FDA Filing
Anemia rises but falls by end of treatment period in pivotal COMFORT-1 trial.